Pharvaris Alternatives & Competitors
12 companies similar to Pharvaris — Pioneering science for patient choice
Companies similar to Pharvaris
Afecta Pharmaceuticals
Creating Precision Medicines...More Efficiently
Irvine, United States
Tvardi Therapeutics
Breakthrough Medicines for Cancer, Chronic Inflammation & Fibrosis
Houston, United States
Nuvamid
A clinical stage biotech focused on the research and use of nucleotides, as therapeutics f...
Nyon, Switzerland
Redx Pharma
Biotech company focusing on the discovery and development of novel targeted medicines to t...
United Kingdom
Rival Readout
Competing with Pharvaris? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Flare Therapeutics
Trailblazing the path to drugging transcription factors to discover precision medicines fo...
Cambridge, United States
Endeavor BioMedicines
Boldly pursuing development of transformational medicines that may restore hope for patien...
San Diego, United States
Synnovation Therapeutics
A precision oncology company focused on small molecule therapies optimized to target key d...
Wilmington, United States
Azome Therapeutics
Developing selective NLRP3 inflammasome inhibitors for severe inflammatory diseases
Sling Therapeutics
Focused on late-stage development of an oral small molecule for the treatment of thyroid e...
Ann Arbor, United States
Lumos Pharma
Transforming Lives with Rare Focus
Austin, United States
Biodexa Pharmaceuticals PLC
Advancing Medicines for a Brighter Future
Cardiff, United Kingdom
Arrakis Therapeutics
Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to...
Waltham, United States
About Pharvaris
Pharvaris, founded in 2015, is a Switzerland-based clinical-stage company at the forefront of developing oral treatments for bradykinin-mediated diseases such as hereditary angioedema (HAE). The company’s slogan, "Pioneering science for patient choice", reflects its dedication to innovative therapeutic options. Special...
Development of oral bradykinin B2 receptor antagonists, Research and clinical trials for hereditary and acquired angioedema, Providing oral alternatives to traditional injection therapies
Patients with hereditary angioedema (HAE), Patients with acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), Healthcare providers managing bradykinin-mediated conditions
Clinical-stage Biotechnology, Bradykinin-B2-Receptor Antagonists, Oral Therapeutics Development, Rare Disorders, Hereditary Angioedema, Small Molecule Drug Discovery, Pharmaceutical Development, Novel Therapeutics, Phase 1 Clinical Trials, Drug Candidate Development, Innovative Medicine, Receptor-mediated Diseases, Non-injectable Therapies, Biotech Leadership
B2B, B2C, D2C
Product Sales, Licensing
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Pharvaris: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Pharvaris on 1 Apr 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
